Xin Lang Cai Jing·2025-08-13 08:08Core Insights - BeiGene (688235.SH) is set to achieve multiple milestone events in the near future, with expectations for significant advancements in its clinical pipeline by the end of 2026 [1] Group 1: Milestones and Expectations - By the end of 2026, the company anticipates that Sotigalimab will receive its first global approval [1] - The BTK CDAC is expected to yield key data, contributing to the company's growth and development [1] - The company's in-house clinical team is advancing over 20 Phase 3 trials, indicating a robust clinical development strategy [1] Group 2: Project Validation and New Developments - The company expects to achieve concept validation data readouts for more than 10 projects, showcasing its commitment to innovation [1] - The research team is set to advance over 10 new molecular entities into clinical stages, reflecting a strong pipeline of potential therapies [1]